Applied Therapeutics Inc. (NASDAQ:APLT - Get Free Report)'s stock price traded down 5% during mid-day trading on Thursday . The company traded as low as $0.51 and last traded at $0.51. 726,203 shares changed hands during trading, a decline of 71% from the average session volume of 2,507,563 shares. The stock had previously closed at $0.54.
Analyst Ratings Changes
A number of research analysts recently issued reports on the company. Wall Street Zen upgraded Applied Therapeutics to a "sell" rating in a research note on Saturday. Royal Bank Of Canada restated a "sector perform" rating and set a $1.50 price target on shares of Applied Therapeutics in a research note on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, Applied Therapeutics currently has a consensus rating of "Hold" and an average target price of $6.10.
Read Our Latest Stock Report on APLT
Applied Therapeutics Price Performance
The stock has a market capitalization of $72.20 million, a PE ratio of -1.19 and a beta of 1.82. The stock has a 50 day moving average of $0.39 and a two-hundred day moving average of $0.46.
Institutional Trading of Applied Therapeutics
A number of institutional investors have recently modified their holdings of APLT. Swiss National Bank purchased a new stake in shares of Applied Therapeutics in the fourth quarter valued at approximately $126,000. Norges Bank purchased a new stake in shares of Applied Therapeutics in the fourth quarter valued at approximately $208,000. Wellington Management Group LLP boosted its stake in shares of Applied Therapeutics by 17.8% in the fourth quarter. Wellington Management Group LLP now owns 237,850 shares of the company's stock valued at $204,000 after buying an additional 35,884 shares in the last quarter. Aristides Capital LLC purchased a new stake in shares of Applied Therapeutics in the fourth quarter valued at approximately $134,000. Finally, Legal & General Group Plc boosted its stake in shares of Applied Therapeutics by 293.9% in the fourth quarter. Legal & General Group Plc now owns 84,018 shares of the company's stock valued at $72,000 after buying an additional 62,686 shares in the last quarter. 98.31% of the stock is currently owned by hedge funds and other institutional investors.
About Applied Therapeutics
(
Get Free Report)
Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.
Read More
Before you consider Applied Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Applied Therapeutics wasn't on the list.
While Applied Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access